www.youtube.com/watch?v=AKBds9vfc0s
Today, my parents and I met with my Oncologist, Dr. VanderWoude to discuss the Surgical Pathology Final Report of the lymph node dissections in which I reported to you last week. Upon review of this report, it is still agreed that I received a "node-negative= no cancer found" diagnosis.
We learned today that there was an additional spot of cancer found in the left breast. First we knew there was one. The MRI report showed two and the surgery claimed there were three as reported in the Pathology Report.
1) Invasive ductal carcinoma, largest lesion, 1.3 cm.
2) Mucinous invasive ductal carcinoma, intermediate-sized lesion, 0.6 cm.
3) Invasive ductal carcinoma, smallest lesion, 0.4 cm.
These have all been identified with no evidence of metastasis.
The Pathology Reports are microscopic and give detail of the dissection biopsy as clearly as can be measured with the naked eye. NOW, the specimen is going to be sent to California to an advanced multigene expression test at the molecular level, with the ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer called the Oncotype DX Breast Cancer Assay test.
About the Oncotype DX Breast Cancer Test and Early Stage Breast Cancer
The Oncotype DX breast cancer assay, is a test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about a patient's individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
The Oncotype DX breast cancer multigene expression test has been extensively evaluated in 14 clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.
Oncotype DX is the only test incorporated in breast cancer treatment guidelines for patients (which is me) with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive.
About the Oncotype DX Breast Cancer Test for DCIS (Ductal Carcinoma In Situ) and Pre-Invasive Breast Cancer
The Oncotype DX Breast Cancer test for DCIS patients is the first clinically validated genomic assay to provide an individualized prediction of the 10-year risk of local recurrence (DCIS or invasive carcinoma) to help guide treatment decision-making in women with ductal carcinoma in situ treated by local excision, with or without tamoxifen (tamoxifen is a drug I might be taking for the hormone therapy piece).
In summary, there will be a treatment plan. Either a short bout with Chemotherapy (four treatments) and the hormone therapy drug (which will be for 5+-years) or just the hormone therapy drug. It will take 2-3 weeks to hear the results of the Oncotype DX Breast Cancer test results.....stay tuned!
Isaiah 26:3 - You will keep in perfect peace him whose mind is steadfast because he trusts in you.
In summary, there will be a treatment plan. Either a short bout with Chemotherapy (four treatments) and the hormone therapy drug (which will be for 5+-years) or just the hormone therapy drug. It will take 2-3 weeks to hear the results of the Oncotype DX Breast Cancer test results.....stay tuned!
Isaiah 26:3 - You will keep in perfect peace him whose mind is steadfast because he trusts in you.
No comments:
Post a Comment